The abstract is read at the publisher; the summary is JClub's.
In immune-positive, ERBB2-negative stage II/III early breast cancer in I-SPY2.2, RT-DXd achieved a modeled 54% pathologic complete response rate, meeting the predefined success threshold.
- Why it matters: Standard chemotherapy exposure remains high for high-risk ERBB2-negative disease, and the trial addresses whether targeted antibody combinations can improve pCR while limiting toxicity.
- What they did: In this phase 2 multicenter adaptively randomized neoadjuvant trial in the US, patients received RT-DXd as block A, with subsequent blocks based on response and subtype; pCR was the primary endpoint.
- The result: Across blocks, overall pCR was similar to control, but among immune-positive patients achieving pCR, 62% needed only block A and 97% avoided anthracycline-based chemotherapy, with ILD occurring in 12.4%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.